1. Natural linoleic acid from marine fungus Eutypella sp. F0219 blocks KEAP1/NRF2 interaction and ameliorates MASLD by targeting FABP4.
- Author
-
Wu CY, Chen Y, Chen MT, Fu TT, Liu J, Liu FF, Xu CJ, Li WS, Li BL, Jiang ZP, Rao Y, and Huang L
- Subjects
- Animals, Humans, Mice, Hep G2 Cells, Lipid Metabolism drug effects, Male, Signal Transduction drug effects, Fatty Liver metabolism, Fatty Liver pathology, Fatty Liver drug therapy, Ascomycota chemistry, Palmitic Acid pharmacology, Mice, Inbred C57BL, NF-E2-Related Factor 2 metabolism, Kelch-Like ECH-Associated Protein 1 metabolism, Kelch-Like ECH-Associated Protein 1 genetics, Fatty Acid-Binding Proteins metabolism, Fatty Acid-Binding Proteins genetics, Linoleic Acid metabolism, Linoleic Acid pharmacology, Hepatocytes metabolism, Hepatocytes drug effects, Hepatocytes pathology, Oxidative Stress drug effects
- Abstract
Ectopic lipid accumulation induced lipotoxicity plays a crucial role in exacerbating the development of metabolic dysfunction-associated steatotic liver disease (MASLD), which affects over 30 % of the worldwide population and 85 % of the obese population. The growing demand for effective therapeutic agents highlights the need for high-efficacy lipotoxicity ameliorators and relevant therapeutic targets in the fight against MASLD. This study aimed to discover natural anti-lipotoxic and anti-MASLD candidates and elucidate the underlying mechanism and therapeutic targets. Utilizing palmitic acid (PA)-induced HepG-2 and primary mouse hepatocyte models, we identified linoleic acid (HN-002), a ligand of fatty acid binding protein 4 (FABP4), from the marine fungus Eutypella sp. F0219. HN-002 dose-dependently prevented lipid overload-induced hepatocyte damage and lipid accumulation, inhibited fatty acid esterification, and ameliorated oxidative stress. These beneficial effects were associated with improvements in mitochondrial adaptive oxidation. HN-002 treatment enhanced lipid transport into mitochondria and oxidation, inhibited mitochondrial depolarization, and reduced mitochondrial ROS (mtROS) level in PA-treated hepatocytes. Mechanistically, HN-002 treatment disrupted the interaction between KEAP1 and NRF2, leading to NRF2 deubiquitylation and nuclear translocation, which activated beneficial metabolic regulation. In vivo, HN-002 treatment (20 mg/kg/per 2 days, i. p.) for 25 days effectively reversed hepatic steatosis and liver injury in the fast/refeeding plus high-fat/high-cholesterol diet induced MASLD mice. These therapeutic effects were associated with enhanced mitochondrial adaptive oxidation and activation of NRF2 signaling in the liver. These data suggest that HN-002 would be an interesting candidate for MASLD by improving mitochondrial oxidation via the FABP4/KEAP1/NRF2 axis. The discovery offers new insights into developing novel anti- MASLD agents derived from marine sources., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF